CONCLUSIONS Office-based bup/nx for clinically stable patients may be a cost-effective alternative to no treatment at a threshold of $100,000/QALY
depending on assumptions about quality-of-life weights. Additional research about quality-of-life benefits and broader health
system and societal cost savings of bup/nx therapy is needed.
Content Type Journal ArticleCategory Original ResearchPages 1-8DOI 10.1007/s11606-011-1962-8Authors
Bruce R. Schackman, Department of Public Health, Weill Cornell Medical College, 402 East 67th Street, New York, NY 10065, USAJared A. Leff, Department of Public Health, Weill Cornell Medical College, 402 East 67th Street, New York, NY 10065, USADaniel Polsky, Division of Internal Medicine, University of Pennsylvania School of Medicine, Phi…
